Review
Weekly chemotherapeutic regimen in metastatic prostate cancer
Affiliations
- PMID: 2674989
Item in Clipboard
Review
Weekly chemotherapeutic regimen in metastatic prostate cancer
Prog Clin Biol Res.
1989.
Abstract
1. A weekly fractionation of EPIRUBICIN at an unchanged dose intensity leads to a significant decrease in toxicity. 2. The weekly administration of 25 mg/m2 EPIRUBICIN is effective in treating hormone refractory prostate carcinoma and completely fulfills the requirements for palliation.
Similar articles
-
Weekly chemotherapeutic regimen in metastatic prostate cancer.Prog Clin Biol Res. 1990;350:187-200. Prog Clin Biol Res. 1990. PMID: 2201043 Review.
-
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.Urol Oncol. 2004 Sep-Oct;22(5):398-403. doi: 10.1016/j.urolonc.2004.05.002. Urol Oncol. 2004. PMID: 15464920 Clinical Trial.
-
Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.Anticancer Res. 1997 Sep-Oct;17(5B):3817-20. Anticancer Res. 1997. PMID: 9427786
-
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.Eur Urol. 1997;32 Suppl 3:81-5. Eur Urol. 1997. PMID: 9267791 Clinical Trial.
-
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11. Cancer Treat Rev. 2008. PMID: 18620815 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical